Eversept Partners LP Acquires 26,179 Shares of Biogen Inc. $BIIB

Eversept Partners LP lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 50.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 77,944 shares of the biotechnology company’s stock after acquiring an additional 26,179 shares during the quarter. Eversept Partners LP’s holdings in Biogen were worth $13,717,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. WPG Advisers LLC boosted its stake in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the period. First Horizon Corp acquired a new position in Biogen in the 4th quarter valued at $30,000. Root Financial Partners LLC raised its holdings in Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 123 shares in the last quarter. GoalVest Advisory LLC acquired a new position in Biogen in the 4th quarter valued at $35,000. Finally, Accredited Wealth Management LLC raised its holdings in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen Stock Up 1.6%

Shares of NASDAQ BIIB opened at $198.67 on Thursday. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The company has a market cap of $29.33 billion, a price-to-earnings ratio of 21.32 and a beta of 0.20. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $205.97. The stock has a 50-day moving average price of $190.05 and a two-hundred day moving average price of $184.70.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts forecast that Biogen Inc. will post 13.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on BIIB shares. Oppenheimer lifted their price objective on Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Barclays started coverage on Biogen in a report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price objective for the company. Morgan Stanley lifted their price objective on Biogen from $200.00 to $206.00 and gave the company an “equal weight” rating in a report on Thursday, April 30th. Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Rothschild & Co Redburn lifted their price objective on Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Biogen presently has an average rating of “Moderate Buy” and a consensus target price of $216.70.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.